<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">37316671</PMID><DateCompleted><Year>2023</Year><Month>07</Month><Day>25</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>619</Volume><Issue>7968</Issue><PubDate><Year>2023</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Genetic stabilization of attenuated oral vaccines against poliovirus types 1 and 3.</ArticleTitle><Pagination><StartPage>135</StartPage><EndPage>142</EndPage><MedlinePgn>135-142</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41586-023-06212-3</ELocationID><Abstract><AbstractText>Vaccination with Sabin, a live attenuated oral polio vaccine (OPV), results in robust intestinal and humoral immunity and has been key to controlling poliomyelitis. As with any RNA virus, OPV evolves rapidly to lose attenuating determinants critical to the reacquisition of virulence<sup>1-3</sup> resulting in vaccine-derived, virulent poliovirus variants. Circulation of these variants within underimmunized populations leads to further evolution of circulating, vaccine-derived poliovirus with higher transmission capacity, representing a significant risk of polio re-emergence. A new type 2 OPV (nOPV2), with promising clinical data on genetic stability and immunogenicity, recently received authorization from the World Health Organization for use in response to circulating, vaccine-derived poliovirus outbreaks. Here we report the development of two additional live attenuated vaccine candidates against type 1 and 3 polioviruses. The candidates were generated by replacing the capsid coding region of nOPV2 with that from Sabin 1 or 3. These chimeric viruses show growth phenotypes similar to nOPV2 and immunogenicity comparable to their parental Sabin strains, but are more attenuated. Our experiments in mice and deep sequencing analysis confirmed that the candidates remain attenuated and preserve all the documented nOPV2 characteristics concerning genetic stability following accelerated virus evolution. Importantly, these vaccine candidates are highly immunogenic in mice as monovalent and multivalent formulations and may contribute to poliovirus eradication.</AbstractText><CopyrightInformation>© 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yeh</LastName><ForeName>Ming Te</ForeName><Initials>MT</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Matthew</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>National Institute for Biological Standards and Control, South Mimms, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carlyle</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-7158-8134</Identifier><AffiliationInfo><Affiliation>National Institute for Biological Standards and Control, South Mimms, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Konopka-Anstadt</LastName><ForeName>Jennifer L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Vaccine Innovation and Access, PATH, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burns</LastName><ForeName>Cara C</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Konz</LastName><ForeName>John</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-8309-5540</Identifier><AffiliationInfo><Affiliation>Center for Vaccine Innovation and Access, PATH, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andino</LastName><ForeName>Raul</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0001-5503-9349</Identifier><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA, USA. Raul.Andino@ucsf.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Macadam</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-8687-1573</Identifier><AffiliationInfo><Affiliation>National Institute for Biological Standards and Control, South Mimms, UK. Andrew.Macadam@nibsc.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>N01AI40085</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AI091575</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AI036178</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>06</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011055">Poliovirus Vaccine, Oral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014613">Vaccines, Attenuated</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Drug Discov. 2023 Aug;22(8):623. doi: 10.1038/d41573-023-00107-8</RefSource><PMID Version="1">37400708</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="Y">Poliomyelitis</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="Y">Poliovirus</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011055" MajorTopicYN="Y">Poliovirus Vaccine, Oral</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014613" MajorTopicYN="Y">Vaccines, Attenuated</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060740" MajorTopicYN="N">Disease Eradication</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>11</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>5</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>7</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>15</Day><Hour>1</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>14</Day><Hour>23</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>6</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37316671</ArticleId><ArticleId IdType="pmc">PMC10322712</ArticleId><ArticleId IdType="doi">10.1038/s41586-023-06212-3</ArticleId><ArticleId IdType="pii">10.1038/s41586-023-06212-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Stern A, et al. The evolutionary pathway to virulence of an RNA virus. Cell. 2017;169:35–46. doi: 10.1016/j.cell.2017.03.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2017.03.013</ArticleId><ArticleId IdType="pmc">PMC5787669</ArticleId><ArticleId IdType="pubmed">28340348</ArticleId></ArticleIdList></Reference><Reference><Citation>Macadam AJ, Stone DM, Almond JW, Minor PD. The 5’ noncoding region and virulence of poliovirus vaccine strains. Trends Microbiol. 1994;2:449–454. doi: 10.1016/0966-842X(94)90803-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0966-842X(94)90803-6</ArticleId><ArticleId IdType="pubmed">7866703</ArticleId></ArticleIdList></Reference><Reference><Citation>Macadam AJ, et al. Genetic basis of attenuation of the Sabin type 2 vaccine strain of poliovirus in primates. Virology. 1993;192:18–26. doi: 10.1006/viro.1993.1003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/viro.1993.1003</ArticleId><ArticleId IdType="pubmed">8390752</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO. Two out of Three Wild Poliovirus Strains Eradicated; https://www.who.int/news-room/feature-stories/detail/two-out-of-three-wild-poliovirus-strains-eradicated (2019).</Citation></Reference><Reference><Citation>WHO. Poliomyelitishttps://www.who.int/news-room/fact-sheets/detail/poliomyelitis (2022).</Citation></Reference><Reference><Citation>Burns CC, Diop OM, Sutter RW, Kew OM. Vaccine-derived polioviruses. J. Infect. Dis. 2014;210:S283–293. doi: 10.1093/infdis/jiu295.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiu295</ArticleId><ArticleId IdType="pubmed">25316847</ArticleId></ArticleIdList></Reference><Reference><Citation>Guest S, Pilipenko E, Sharma K, Chumakov K, Roos RP. Molecular mechanisms of attenuation of the Sabin strain of poliovirus type 3. J. Virol. 2004;78:11097–11107. doi: 10.1128/JVI.78.20.11097-11107.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.78.20.11097-11107.2004</ArticleId><ArticleId IdType="pmc">PMC521805</ArticleId><ArticleId IdType="pubmed">15452230</ArticleId></ArticleIdList></Reference><Reference><Citation>Lauring AS, Jones JO, Andino R. Rationalizing the development of live attenuated virus vaccines. Nat. Biotechnol. 2010;28:573–579. doi: 10.1038/nbt.1635.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.1635</ArticleId><ArticleId IdType="pmc">PMC2883798</ArticleId><ArticleId IdType="pubmed">20531338</ArticleId></ArticleIdList></Reference><Reference><Citation>GPEI. Polio Eradication Strategy 2022–2026: Delivering on a Promisehttps://polioeradication.org/gpei-strategy-2022-2026/ (2021).</Citation></Reference><Reference><Citation>Lai YA, Chen X, Kunasekaran M, Rahman B, MacIntyre CR. Global epidemiology of vaccine-derived poliovirus 2016–2021: a descriptive analysis and retrospective case-control study. EClinicalMedicine. 2022;50:101508. doi: 10.1016/j.eclinm.2022.101508.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2022.101508</ArticleId><ArticleId IdType="pmc">PMC9240990</ArticleId><ArticleId IdType="pubmed">35784443</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO. Global Circulating Vaccine-Derived Poliovirus (cVDPV) as of 31 January 2023; https://polioeradication.org/wp-content/uploads/2023/02/weekly-polio-analyses-cVDPV-20230131.pdf (2023).</Citation></Reference><Reference><Citation>Macklin GR, et al. Evolving epidemiology of poliovirus serotype 2 following withdrawal of the serotype 2 oral poliovirus vaccine. Science. 2020;368:401–405. doi: 10.1126/science.aba1238.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aba1238</ArticleId><ArticleId IdType="pmc">PMC10805349</ArticleId><ArticleId IdType="pubmed">32193361</ArticleId></ArticleIdList></Reference><Reference><Citation>Manor Y, et al. Detection of poliovirus circulation by environmental surveillance in the absence of clinical cases in Israel and the Palestinian authority. J. Clin. Microbiol. 1999;37:1670–1675. doi: 10.1128/JCM.37.6.1670-1675.1999.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.37.6.1670-1675.1999</ArticleId><ArticleId IdType="pmc">PMC84919</ArticleId><ArticleId IdType="pubmed">10325305</ArticleId></ArticleIdList></Reference><Reference><Citation>Link-Gelles R, et al. Public health response to a case of paralytic poliomyelitis in an unvaccinated person and detection of poliovirus in wastewater — New York, June–August 2022. MMWR Morb. Mort. Wkly Rep. 2022;71:1065–1068. doi: 10.15585/mmwr.mm7133e2.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7133e2</ArticleId><ArticleId IdType="pmc">PMC9400530</ArticleId><ArticleId IdType="pubmed">35980868</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryerson AB, et al. Wastewater testing and detection of poliovirus type 2 genetically linked to virus isolated from a paralytic polio case — New York, March 9–October 11, 2022. MMWR Morb. Mort. Wkly Rep. 2022;71:1418–1424. doi: 10.15585/mmwr.mm7144e2.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7144e2</ArticleId><ArticleId IdType="pmc">PMC9639435</ArticleId><ArticleId IdType="pubmed">36327157</ArticleId></ArticleIdList></Reference><Reference><Citation>Macadam AJ, et al. Correlation of RNA secondary structure and attenuation of Sabin vaccine strains of poliovirus in tissue culture. Virology. 1992;189:415–422. doi: 10.1016/0042-6822(92)90565-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0042-6822(92)90565-7</ArticleId><ArticleId IdType="pubmed">1641974</ArticleId></ArticleIdList></Reference><Reference><Citation>Macadam AJ, et al. Rational design of genetically stable, live-attenuated poliovirus vaccines of all three serotypes: relevance to poliomyelitis eradication. J. Virol. 2006;80:8653–8663. doi: 10.1128/JVI.00370-06.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00370-06</ArticleId><ArticleId IdType="pmc">PMC1563845</ArticleId><ArticleId IdType="pubmed">16912313</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeh MT, et al. Engineering the live-attenuated polio vaccine to prevent reversion to virulence. Cell Host Microbe. 2020;27:736–751. doi: 10.1016/j.chom.2020.04.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2020.04.003</ArticleId><ArticleId IdType="pmc">PMC7566161</ArticleId><ArticleId IdType="pubmed">32330425</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahid R, et al. Evaluating stability of attenuated Sabin and two novel type 2 oral poliovirus vaccines in children. NPJ Vaccines. 2022;7:19. doi: 10.1038/s41541-022-00437-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41541-022-00437-5</ArticleId><ArticleId IdType="pmc">PMC8837630</ArticleId><ArticleId IdType="pubmed">35149714</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahid R, et al. Genetic and phenotypic stability of poliovirus shed from infants who received novel type 2 or Sabin type 2 oral poliovirus vaccines in Panama: an analysis of two clinical trials. Lancet Microbe. 2022;3:e912–e921. doi: 10.1016/S2666-5247(22)00254-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-5247(22)00254-3</ArticleId><ArticleId IdType="pmc">PMC9712124</ArticleId><ArticleId IdType="pubmed">36332645</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahid R, et al. Assessment of genetic changes and neurovirulence of shed Sabin and novel type 2 oral polio vaccine viruses. NPJ Vaccines. 2021;6:94. doi: 10.1038/s41541-021-00355-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41541-021-00355-y</ArticleId><ArticleId IdType="pmc">PMC8322168</ArticleId><ArticleId IdType="pubmed">34326330</ArticleId></ArticleIdList></Reference><Reference><Citation>Konz JO, et al. Evaluation and validation of next-generation sequencing to support lot release for a novel type 2 oral poliovirus vaccine. Vaccine X. 2021;8:100102. doi: 10.1016/j.jvacx.2021.100102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jvacx.2021.100102</ArticleId><ArticleId IdType="pmc">PMC8233139</ArticleId><ArticleId IdType="pubmed">34195600</ArticleId></ArticleIdList></Reference><Reference><Citation>Coster ID, et al. Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in healthy adults: two clinical trials. Lancet. 2021;397:39–50. doi: 10.1016/S0140-6736(20)32541-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32541-1</ArticleId><ArticleId IdType="pmc">PMC7811203</ArticleId><ArticleId IdType="pubmed">33308429</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO. First Ever Vaccine Listed Under WHO Emergency Use; https://www.who.int/news/item/13-11-2020-first-ever-vaccine-listed-under-who-emergency-use (2020).</Citation></Reference><Reference><Citation>Mirzoev A, et al. Assessment of serological responses following vaccination campaigns with type 2 novel oral polio vaccine: a population-based study in Tajikistan in 2021. Lancet Glob. Health. 2022;10:e1807–e1814. doi: 10.1016/S2214-109X(22)00412-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2214-109X(22)00412-0</ArticleId><ArticleId IdType="pmc">PMC9681660</ArticleId><ArticleId IdType="pubmed">36400086</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO. Statement of the Thirtieth Polio IHR Emergency Committee; https://www.who.int/news/item/23-11-2021-statement-of-the-thirtieth-polio-ihr-emergency-committee (2021).</Citation></Reference><Reference><Citation>Bandyopadhyay, A. S. &amp; Zipursky, S. A novel tool to eradicate an ancient scourge: the novel oral polio vaccine type 2 story. Lancet Infect. Dis. 10.1016/s1473-3099(22)00582-5 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36162417</ArticleId></ArticleIdList></Reference><Reference><Citation>Bandyopadhyay AS, et al. Safety and immunogenicity of inactivated poliovirus vaccine schedules for the post-eradication era: a randomised open-label, multicentre, phase 3, non-inferiority trial. Lancet Infect. Dis. 2021;21:559–568. doi: 10.1016/S1473-3099(20)30555-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(20)30555-7</ArticleId><ArticleId IdType="pmc">PMC7992032</ArticleId><ArticleId IdType="pubmed">33284114</ArticleId></ArticleIdList></Reference><Reference><Citation>Sáez-Llorens X, et al. Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in children and infants: two clinical trials. Lancet. 2021;397:27–38. doi: 10.1016/S0140-6736(20)32540-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32540-X</ArticleId><ArticleId IdType="pmc">PMC7811205</ArticleId><ArticleId IdType="pubmed">33308427</ArticleId></ArticleIdList></Reference><Reference><Citation>Damme PV, et al. The safety and immunogenicity of two novel live attenuated monovalent (serotype 2) oral poliovirus vaccines in healthy adults: a double-blind, single-centre phase 1 study. Lancet. 2019;394:148–158. doi: 10.1016/S0140-6736(19)31279-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(19)31279-6</ArticleId><ArticleId IdType="pmc">PMC6626986</ArticleId><ArticleId IdType="pubmed">31174831</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodfellow I, et al. Identification of a cis-acting replication element within the poliovirus coding region. J. Virol. 2000;74:4590–4600. doi: 10.1128/JVI.74.10.4590-4600.2000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.74.10.4590-4600.2000</ArticleId><ArticleId IdType="pmc">PMC111979</ArticleId><ArticleId IdType="pubmed">10775595</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalkowska DA, et al. Updated characterization of outbreak response strategies for 2019–2029: impacts of using a novel type 2 oral poliovirus vaccine strain. Risk Anal. 2021;41:329–348. doi: 10.1111/risa.13622.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/risa.13622</ArticleId><ArticleId IdType="pmc">PMC7887065</ArticleId><ArticleId IdType="pubmed">33174263</ArticleId></ArticleIdList></Reference><Reference><Citation>Westrop GD, et al. Genetic basis of attenuation of the Sabin type 3 oral poliovirus vaccine. J. Virol. 1989;63:1338–1344. doi: 10.1128/jvi.63.3.1338-1344.1989.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.63.3.1338-1344.1989</ArticleId><ArticleId IdType="pmc">PMC247831</ArticleId><ArticleId IdType="pubmed">2536836</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren RB, Moss EG, Racaniello VR. Identification of two determinants that attenuate vaccine-related type 2 poliovirus. J. Virol. 1991;65:1377–1382. doi: 10.1128/jvi.65.3.1377-1382.1991.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.65.3.1377-1382.1991</ArticleId><ArticleId IdType="pmc">PMC239915</ArticleId><ArticleId IdType="pubmed">1847458</ArticleId></ArticleIdList></Reference><Reference><Citation>Neverov A, Chumakov K. Massively parallel sequencing for monitoring genetic consistency and quality control of live viral vaccines. Proc. Natl Acad. Sci. USA. 2010;107:20063–20068. doi: 10.1073/pnas.1012537107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1012537107</ArticleId><ArticleId IdType="pmc">PMC2993378</ArticleId><ArticleId IdType="pubmed">21041640</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO. Neurovirulence Test of Types 1, 2 or 3 Live Attenuated Poliomyelitis Vaccines (Oral) in Transgenic Mice Susceptible to Poliovirus; https://www.who.int/publications/m/item/neurovirulence-test-sop-of-types-1-2-or-3-opv-in-transgenic-mice-susceptible-to-poliovirus (2015).</Citation></Reference><Reference><Citation>Rouzine IM, Rodrigo A, Coffin JM. Transition between stochastic evolution and deterministic evolution in the presence of selection: general theory and application to virology. Microbiol. Mol. Biol. Rev. 2001;65:151–155. doi: 10.1128/MMBR.65.1.151-185.2001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MMBR.65.1.151-185.2001</ArticleId><ArticleId IdType="pmc">PMC99023</ArticleId><ArticleId IdType="pubmed">11238990</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowe A, Ferguson GL, Minor PD, Macadam AJ. Coding changes in the poliovirus protease 2A compensate for 5’NCR domain V disruptions in a cell-specific manner. Virology. 2000;269:284–293. doi: 10.1006/viro.2000.0244.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/viro.2000.0244</ArticleId><ArticleId IdType="pubmed">10753707</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin J, et al. Genetic characterization of novel oral polio vaccine type 2 viruses during initial use phase under emergency use listing — worldwide, March–October 2021. MMWR Morbid. Mort. Wkly Rep. 2022;71:786–790. doi: 10.15585/mmwr.mm7124a2.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7124a2</ArticleId><ArticleId IdType="pubmed">35709073</ArticleId></ArticleIdList></Reference><Reference><Citation>Minor PD, Ferguson M, Evans DMA, Almond JW, Icenogle JP. Antigenic structure of polioviruses of serotypes 1, 2 and 3. J. Gen. Virol. 1986;67:1283–1291. doi: 10.1099/0022-1317-67-7-1283.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/0022-1317-67-7-1283</ArticleId><ArticleId IdType="pubmed">2425046</ArticleId></ArticleIdList></Reference><Reference><Citation>Bannwarth L, et al. Structural studies of virus–antibody immune complexes (poliovirus type I): characterization of the epitopes in 3D. Mol. Immunol. 2015;63:279–286. doi: 10.1016/j.molimm.2014.07.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molimm.2014.07.014</ArticleId><ArticleId IdType="pubmed">25146483</ArticleId></ArticleIdList></Reference><Reference><Citation>Gast, C. et al. Fecal shedding of two novel live attenuated oral poliovirus type 2 vaccines candidates by healthy bOPV/IPV-vaccinated infants: two randomized clinical trials. J. Infect. Dis. 226, jiab507 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9470102</ArticleId><ArticleId IdType="pubmed">34610135</ArticleId></ArticleIdList></Reference><Reference><Citation>Taffs RE, et al. Genetic stability and mutant selection in Sabin 2 strain of oral poliovirus vaccine grown under different cell culture conditions. Virology. 1995;209:366–373. doi: 10.1006/viro.1995.1268.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/viro.1995.1268</ArticleId><ArticleId IdType="pubmed">7778271</ArticleId></ArticleIdList></Reference><Reference><Citation>Brickley EB, et al. Intestinal antibody responses to 2 novel live attenuated type 2 oral poliovirus vaccines in healthy adults in Belgium. J. Infect. Dis. 2020;226:287–291. doi: 10.1093/infdis/jiaa783.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiaa783</ArticleId><ArticleId IdType="pmc">PMC9400418</ArticleId><ArticleId IdType="pubmed">33367918</ArticleId></ArticleIdList></Reference><Reference><Citation>PATH. Study of novel types 1 and 3 oral poliomyelitis vaccines. https://clinicaltrials.gov/ct2/show/NCT04529538 (2023).</Citation></Reference><Reference><Citation>Bandyopadhyay AS, Garon J, Seib K, Orenstein WA. Polio vaccination: past, present and future. Future Microbiol. 2015;10:791–808. doi: 10.2217/fmb.15.19.</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/fmb.15.19</ArticleId><ArticleId IdType="pubmed">25824845</ArticleId></ArticleIdList></Reference><Reference><Citation>GPEI. GPEI Statement on cVDPV2 Detections in Burundi and Democratic Republic of the Congo; https://polioeradication.org/news-post/gpei-statement-on-cvdpv2-detections-in-burundi-and-democratic-republic-of-the-congo/ (2023).</Citation></Reference><Reference><Citation>Roberts, L. Polio cases in Africa linked to new oral vaccine. Sciencehttps://www.science.org/content/article/first-polio-cases-linked-new-oral-vaccine-detected-africa (2023).</Citation></Reference><Reference><Citation>Burrill, C. P., Strings, V. R. &amp; Andino, R. Poliovirus: generation, quantification, propagation, purification, and storage. Curr. Protoc. Microbiol.Ch. 15, 15H.1.1–15H.1.27 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4826561</ArticleId><ArticleId IdType="pubmed">23686830</ArticleId></ArticleIdList></Reference><Reference><Citation>Hierholzer, J. C. &amp; Killington, R. A. Virus isolation and quantitation. Virology Methods Manual1996, 25–46 (2007).</Citation></Reference><Reference><Citation>Wilm A, et al. LoFreq: a sequence-quality aware, ultra-sensitive variant caller for uncovering cell-population heterogeneity from high-throughput sequencing datasets. Nucleic Acids Res. 2012;40:11189–11201. doi: 10.1093/nar/gks918.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gks918</ArticleId><ArticleId IdType="pmc">PMC3526318</ArticleId><ArticleId IdType="pubmed">23066108</ArticleId></ArticleIdList></Reference><Reference><Citation>Knowlson S, et al. New strains intended for the production of inactivated polio vaccine at low-containment after eradication. PLoS Pathog. 2015;11:e1005316. doi: 10.1371/journal.ppat.1005316.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1005316</ArticleId><ArticleId IdType="pmc">PMC4699825</ArticleId><ArticleId IdType="pubmed">26720150</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark MF, Lister RM, Bar-Joseph M. ELISA techniques. Methods Enzymol. 1986;118:742–766. doi: 10.1016/0076-6879(86)18114-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0076-6879(86)18114-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Holm, S. A simple sequentially rejective multiple test procedure. Scand. Stat. Theory Appl.6, 65–70 (2019).</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>